ABSTRACT :

Objective: In patients treated through the application of intracavernosal alprostadil in sec-ond-line treatment due to erectile dysfunction, the effect of the treatment on sexual functions measured with a 15-question International Index of Erectile Function (IIEF-15) questionnaire was investigated in this study.

Material and Methods: Twenty-one patients treated due to erectile dysfunction between June 2018-October 2019, taking inadequate response from first-line treatment modalities, were applied intracavernosal alprostadil in second-line treat-ment and continued it for more than 12 weeks were included in the study, retrospectively. Ages, comorbid diseases, drug usage duration, drug-re-lated side effects, penile Doppler ultrasonography (USG) parameters before application and the erec-tion functions before and 12 weeks after drug use were evaluated with IIEF-15 form for the patients. Intracavernosal alprostadil was started with a dose of 5 μg and was continued with a dose of 10 μg as the result of dose titration.

Results: The mean peak systolic blood flow velocity (PS) value of the patients was 24.4 ±15.1 cm/sec, and the mean end-diastolic flow veloc-ity (ED) value was measured as 4.3±4.5 cm/sec based on the pre-treatment penile Doppler USG. Although the IIEF scores were measured in the 12th week, mean drug usage durations were mea-sured as 21.9±16.6 weeks. Erectile Function Score was 9.2±5.3 before application; it was detected as 20.33±6.2 after the application. Orgasmic Func-tion Score was 3.2±2.5 before application; it was detected as 7.5±2.4 after the application. Sexual Desire Score was 3.72±1.48 before application; it was detected as 8.9±1.4 after the application. Intercourse Satisfaction Score was 3.7±2.8 before appli-cation; it was detected as 9.1±2.7 after the application. Overall Satis-faction Score was 4±1.7 before application; it was detected as 8.1±1.7 after the application (All parameters p<0.001).

Conclusion: Intracavernosal alprostadil treatment used in erectile dysfunction second-line treatment is a cost-effective and efficient treatment method with a tolerable side effect profile and provides recovery in sexual parameters that can be measured with IIEF-15 parameters.

Keywords: Alprostadil, erectile dysfunction, intracavernosal treatment.

<p style=Objective: In patients treated through the application of intracavernosal alprostadil in sec-ond-line treatment due to erectile dysfunction, the effect of the treatment on sexual functions measured with a 15-question International Index of Erectile Function (IIEF-15) questionnaire was investigated in this study.

Material and Methods: Twenty-one patients treated due to erectile dysfunction between June 2018-October 2019, taking inadequate response from first-line treatment modalities, were applied intracavernosal alprostadil in second-line treat-ment and continued it for more than 12 weeks were included in the study, retrospectively. Ages, comorbid diseases, drug usage duration, drug-re-lated side effects, penile Doppler ultrasonography (USG) parameters before application and the erec-tion functions before and 12 weeks after drug use were evaluated with IIEF-15 form for the patients. Intracavernosal alprostadil was started with a dose of 5 μg and was continued with a dose of 10 μg as the result of dose titration.

Results: The mean peak systolic blood flow velocity (PS) value of the patients was 24.4 ±15.1 cm/sec, and the mean end-diastolic flow veloc-ity (ED) value was measured as 4.3±4.5 cm/sec based on the pre-treatment penile Doppler USG. Although the IIEF scores were measured in the 12th week, mean drug usage durations were mea-sured as 21.9±16.6 weeks. Erectile Function Score was 9.2±5.3 before application; it was detected as 20.33±6.2 after the application. Orgasmic Func-tion Score was 3.2±2.5 before application; it was detected as 7.5±2.4 after the application. Sexual Desire Score was 3.72±1.48 before application; it was detected as 8.9±1.4 after the application. Intercourse Satisfaction Score was 3.7±2.8 before appli-cation; it was detected as 9.1±2.7 after the application. Overall Satis-faction Score was 4±1.7 before application; it was detected as 8.1±1.7 after the application (All parameters p<0.001).

Conclusion: Intracavernosal alprostadil treatment used in erectile dysfunction second-line treatment is a cost-effective and efficient treatment method with a tolerable side effect profile and provides recovery in sexual parameters that can be measured with IIEF-15 parameters.

Keywords: Alprostadil, erectile dysfunction, intracavernosal treatment.

" class="img-fluid" />